Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.
Vilsbøll
Tina
T
Department of Internal Medicine, Gentofte Hospital, Hellerup, Denmark. t.vilsboll@dadlnet.dk
Zdravkovic
Milan
M
Le-Thi
Tu
T
Krarup
Thure
T
Schmitz
Ole
O
Courrèges
Jean-Pierre
JP
Verhoeven
Robert
R
Bugánová
Ingrid
I
Madsbad
Sten
S
D000328:Adult; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069450:Liraglutide; D010919:Placebos; D012449:Safety; D015431:Weight Loss
D001786:Blood Glucose; D052216:Glucagon-Like Peptide 1; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000069450:Liraglutide; D010919:Placebos